123 related articles for article (PubMed ID: 2450240)
1. Cardiac and coronary vasodilator effects of the novel cardiotonic agent, MCI-154, assessed in isolated, blood-perfused dog heart preparations.
Hosono M; Taira N
J Cardiovasc Pharmacol; 1987 Dec; 10(6):692-8. PubMed ID: 2450240
[TBL] [Abstract][Full Text] [Related]
2. Profile of cardiac and coronary vasodilator effects of MS-857, a novel cardiotonic agent, assessed in isolated, blood-perfused heart preparations of the dog.
Maruyama M; Kamiya J; Kobari T
J Cardiovasc Pharmacol; 1989 Nov; 14(5):777-82. PubMed ID: 2481193
[TBL] [Abstract][Full Text] [Related]
3. Cardiac and coronary vasodilator profile of pimobendan, a new cardiotonic drug, revealed by use of isolated, blood-perfused dog heart preparations.
Imagawa J; Satoh K; Taira N
Heart Vessels; 1987; 3(4):182-9. PubMed ID: 3453824
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of cardiovascular profiles of milrinone and amrinone by use of isolated, blood-perfused dog heart preparations.
Sato Y; Wada Y; Taira N
Heart Vessels; 1986; 2(4):213-20. PubMed ID: 3571104
[TBL] [Abstract][Full Text] [Related]
5. Coronary vasodilator and cardiac effects of NKY-722, a novel hydrophilic 1,4-dihydropyridine derivative, in the blood-perfused dog heart.
Imagawa J; Satoh K; Taira N
Cardiovasc Drugs Ther; 1989 Mar; 3(1):81-90. PubMed ID: 2487526
[TBL] [Abstract][Full Text] [Related]
6. Inotropic versus chronotropic, dromotropic, and coronary vasodilator actions of DPI 201-106, a novel positive inotropic agent, in the dog heart.
Takahashi K; Endoh M; Taira N
J Cardiovasc Pharmacol; 1987 Apr; 9(4):451-60. PubMed ID: 2438508
[TBL] [Abstract][Full Text] [Related]
7. Separation of the coronary vasodilator from the cardiac effects of PN 200-110, a new dihydropyridine calcium antagonist, in the dog heart.
Wada Y; Satoh K; Taira N
J Cardiovasc Pharmacol; 1985; 7(1):190-6. PubMed ID: 2580142
[TBL] [Abstract][Full Text] [Related]
8. Cardiac effects of the novel pyridazinone derivative 6-[4-[2-[3-(5-chloro-2-cyanophenoxy)-2-hydroxypropylamino]- 2- methylpropylamino]phenyl]-4,5-dihydro-5-methyl-3(2H) pyridazinone monoethyl maleate and its metabolite in isolated heart preparations of guinea pigs and dogs.
Ishimori T; Gotanda K; Sasaki T; Shinbo A; Asano H; Miyazawa K; Miyasaka K
Arzneimittelforschung; 1994 May; 44(5):583-8. PubMed ID: 7912931
[TBL] [Abstract][Full Text] [Related]
9. Profile of coronary vasodilator and cardiac actions of bepridil revealed by use of isolated, blood-perfused heart preparations of the dog.
Kawada M; Satoh K; Taira N
J Cardiovasc Pharmacol; 1983; 5(4):604-12. PubMed ID: 6193358
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of MDL 17043 and MDL 19205, new positive inotropic agents, by use of isolated, blood-perfused dog-heart preparations.
Wada Y; Taira N
Heart Vessels; 1986; 2(1):29-35. PubMed ID: 2941407
[TBL] [Abstract][Full Text] [Related]
11. Coronary vasodilator compared to cardiac effects of PY 108-068, a new dihydropyridine vasodilator, on isolated, blood-perfused dog-heart preparations.
Wada Y; Satoh K; Taira N
J Cardiovasc Pharmacol; 1984; 6(5):881-7. PubMed ID: 6209495
[TBL] [Abstract][Full Text] [Related]
12. Profile of cardiovascular effects of NKH477, a novel forskolin derivative, assessed in isolated, blood-perfused dog heart preparations: comparison with isoproterenol.
Ishizuka O; Hosono M; Nakamura K
J Cardiovasc Pharmacol; 1992 Aug; 20(2):261-7. PubMed ID: 1381017
[TBL] [Abstract][Full Text] [Related]
13. Analyses of the cardiac action of the bradycardic agent, AQ-A 39, by use of isolated, blood-perfused dog-heart preparations.
Kawada M; Satoh K; Taira N
J Pharmacol Exp Ther; 1984 Feb; 228(2):484-90. PubMed ID: 6694121
[TBL] [Abstract][Full Text] [Related]
14. Selectivity of alinidine, a bradycardic agent, for SA nodal automaticity versus other cardiac activities in isolated, blood-perfused dog-heart preparations.
Kawada M; Satoh K; Taira N
Arch Int Pharmacodyn Ther; 1984 Nov; 272(1):88-102. PubMed ID: 6517649
[TBL] [Abstract][Full Text] [Related]
15. Coronary vasodilator versus cardiac effects of MCI-176, a novel quinazolinone calcium antagonist, in the dog heart.
Hosono M; Taira N
J Cardiovasc Pharmacol; 1987 Jun; 9(6):633-40. PubMed ID: 2442528
[TBL] [Abstract][Full Text] [Related]
16. Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, on the dog heart.
Taira N; Endoh M; Iijima T; Satoh K; Yanagisawa T; Yamashita S; Maruyama M; Kawada M; Morita T; Wada Y
Arzneimittelforschung; 1984; 34(3A):347-55. PubMed ID: 6331465
[TBL] [Abstract][Full Text] [Related]
17. Is the cardiovascular profile of BRL 34915 characteristic of potassium channel activators?
Gotanda K; Satoh K; Taira N
J Cardiovasc Pharmacol; 1988 Aug; 12(2):239-46. PubMed ID: 2459556
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of coronary vasodilator and cardiac effects of nitrendipine by use of isolated, blood-perfused dog heart preparations.
Satoh K; Wada Y; Taira N
Arzneimittelforschung; 1986; 36(1):35-9. PubMed ID: 2937413
[TBL] [Abstract][Full Text] [Related]
19. Are the cardiovascular effects of gentamicin similar to those of calcium antagonists?
Gotanda K; Yanagisawa T; Satoh K; Taira N
Jpn J Pharmacol; 1988 Jul; 47(3):217-27. PubMed ID: 3221528
[TBL] [Abstract][Full Text] [Related]
20. Cardiac versus coronary vasodilator actions of KB-944, a new calcium antagonist, assessed in isolated, blood-perfused heart preparations of dogs.
Taira N; Kawada M; Satoh K
J Cardiovasc Pharmacol; 1983; 5(3):349-56. PubMed ID: 6191131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
